AIxCrypto Holdings, Inc. (AIXC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
5857 Owens Avenue
Carlsbad, CA 92008
United States of America (the)
Phone
760 452 8111
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
10
First IPO Date
June 23, 2015
| Name | Title | Pay | Year Born |
| Jiawei Wang | CEO & Director | 303,000 | 1991 |
| Jie Sheng | President & CFO | 30,625 | 1984 |
| Christopher L. Lotz | Vice President of Finance & Corporate Secretary | 397,344 | 1965 |
| Michael S. Poirier | Chief Operating Officer | 686,526 | 1956 |
| Koti Meka | Chief Financial Officer | 0 | 1970 |
| Andrew Grossman | Head of Legal | 0 | N/A |
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.